MYOK News and Press, MyoKardia Inc. From 10/07/20

Bristol Myers Squibb is making a big $13-billion deal, less than a year after the Celgene acquisition closed. That purchase is delivering according to, and even exceeding, expectations. While the situation looked quite reasonable, I feel that the latest purchase is a bit too rushe...

BMY is taking over MyoKardia for $13 billion. MyoKardia's lead drug could generate peak sales of ~$2 billion, there are other pipeline candidates aimed at treating CV diseases on top of that. This bolsters BMY's position in the very large CV disease market. Even though the acq...

On Monday, Bristol Myers Squibb (NYSE: BMY) announced that it had agreed to acquire MyoKardia (NASDAQ: MYOK) for $13.1 billion in cash. It's offering $225 per share for Myokardia, a 61% premium to the stock's most recent closing price. The deal, which is expected to clos...

The stock market bounced back on Monday from its losses late last week, as the initial news of President Donald Trump testing positive for COVID-19 gave way to positive comments about his ongoing recovery. It's not uncommon for stocks to fall going into a weekend during which there's consid...

Gainers: Greenpro Capital (GRNQ) +85%.MyoKardia (MYOK) +58%.Westwater Resources (WWR) +53%.Eidos Therapeutics (EIDX) +40%.Scully Royalty (SRL) +34%.Enlivex Therapeutics (ENLV) +28%.Humanigen (HGEN) +24%.Corvus Pharmaceuticals (CRVS) +22%.Piedmont Lithium (PLL) +22%.Pulse Biosciences (PLS...

Gainers: MyoKardia (MYOK) +58%, Eidos Therapeutics (EIDX) +41%, Enlivex Therapeutics (ENLV) +25%, Humanigen (HGEN) +28%, Corvus Pharmaceuticals (CRVS) +26%.Losers: Xtant Medical Holdings (XTNT) -15%, Curis (CRIS) -7%, Immunome (...

Shares of the heart disease specialist MyoKardia (NASDAQ: MYOK) jumped by a healthy 59% in pre-market trading Monday morning. The biopharma's stock ripped higher in early-morning action today in response to a $13.1 billion definitive merger agreement with Bristol Myers Squibb ...

MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals (CRVS) +38% on co-foun...

Bristol Myers Squibb (BMY) accelerates the expansion of its cardiovascular portfolio by acquiring MyoKardia (MYOK) for $13.1B, or $225/share in cash.The company expects to finance the acquisition with a combination of cash and debt and anticipates its closing during 4Q20. “The acq...

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval ...